Search Results - "CLELAND, J. L"

Refine Results
  1. 1

    The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation by Cleland, J L, Powell, M F, Shire, S J

    “…The biochemical literature has been surveyed to present an overview of the three most common protein degradation pathways: protein aggregation, deamidation,…”
    Get more information
    Journal Article
  2. 2

    Single-administration vaccines: controlled-release technology to mimic repeated immunizations by Cleland, Jeffrey L

    Published in Trends in Biotechnology (1999)
    “…The most effective mechanism for the elimination of disease from society is the use of vaccinations, but these often require repeated administration. However,…”
    Get full text
    Book Review Journal Article
  3. 3

    Antioxidants for prevention of methionine oxidation in recombinant monoclonal antibody HER2 by Lam, X M, Yang, J Y, Cleland, J L

    Published in Journal of pharmaceutical sciences (01-11-1997)
    “…Recombinant humanized monoclonal antibody HER2, rhuMAb HER2, in liquid formulations undergoes oxidation when exposed to intense light and elevated temperatures…”
    Get more information
    Journal Article
  4. 4

    Tween protects recombinant human growth hormone against agitation-induced damage via hydrophobic interactions by Bam, N B, Cleland, J L, Yang, J, Manning, M C, Carpenter, J F, Kelley, R F, Randolph, T W

    Published in Journal of pharmaceutical sciences (01-12-1998)
    “…In the absence of surfactants, recombinant human growth hormone (rhGH) rapidly forms insoluble aggregates during agitation. The nonionic surfactant Tween 20,…”
    Get more information
    Journal Article
  5. 5

    Sustained release of recombinant human insulin-like growth factor-I for treatment of diabetes by Lam, Xanthe M., Duenas, Eileen T., Daugherty, Ann L., Levin, Nancy, Cleland, Jeffrey L.

    Published in Journal of controlled release (03-07-2000)
    “…Recombinant human insulin-like growth factor-I (rhIGF-I) was found to improve glycemic control and enhance insulin sensitivity in patients with a syndrome of…”
    Get full text
    Journal Article
  6. 6

    Aggregation of recombinant human interferon gamma: kinetics and structural transitions by Kendrick, B S, Cleland, J L, Lam, X, Nguyen, T, Randolph, T W, Manning, M C, Carpenter, J F

    Published in Journal of pharmaceutical sciences (01-09-1998)
    “…Protein aggregation is a complex phenomenon that can occur in vitro and in vivo, usually resulting in the loss of the protein's biological activity. While many…”
    Get more information
    Journal Article
  7. 7

    The stabilization and encapsulation of human growth hormone into biodegradable microspheres by JOHNSON, O. L, JAWOROWICZ, W, JONES, A. J. S, PUTNEY, S. D, CLELAND, J. L, BAILEY, L, CHARNIS, M, DUENAS, E, WU, C, SHEPARD, D, MAGIL, S, LAST, T

    Published in Pharmaceutical research (01-06-1997)
    “…To produce and evaluate sustained-acting formulations of recombinant human growth hormone (rhGH) made by a novel microencapsulation process. The protein was…”
    Get full text
    Journal Article
  8. 8

    Polyethylene glycol enhanced refolding of bovine carbonic anhydrase B. Reaction stoichiometry and refolding model by CLELAND, J. L, HEDGEPETH, C, WANG, D. I. C

    Published in The Journal of biological chemistry (05-07-1992)
    “…Polyethylene glycol (PEG) inhibited aggregation during refolding of bovine carbonic anhydrase B (CAB) through the formation of a nonassociating…”
    Get full text
    Journal Article
  9. 9

    Intracranial delivery of recombinant nerve growth factor : Release kinetics and protein distribution for three delivery systems by SALTZMAN, W. M, MAK, M. W, MAHONEY, M. J, DUENAS, E. T, CLELAND, J. L

    Published in Pharmaceutical research (01-02-1999)
    “…Three different polymeric delivery systems, composed of either poly(ethylene-co-vinyl acetate) (EVAc) or poly(lactide-co-glycolide) (PLGA), were used to…”
    Get full text
    Journal Article
  10. 10

    Factors affecting the in vitro release of recombinant human interferon-gamma (rhIFN-gamma) from PLGA microspheres by Yang, J, Cleland, J L

    Published in Journal of pharmaceutical sciences (01-08-1997)
    “…A long-acting depot formulation of recombinant human interferon-gamma (rhIFN-gamma) was achieved by microencapsulation of rhIFN-gamma in polylactic-coglycolic…”
    Get more information
    Journal Article
  11. 11

    A slow release formulation of insulin as a treatment for osteoarthritis by Cai, L., Okumu, F.W., Cleland, J.L., Beresini, M., Hogue, D., Lin, Z., Filvaroff, E.H.

    Published in Osteoarthritis and cartilage (01-09-2002)
    “…Objective To examine the potential of insulin, in a sustained delivery system, as a treatment for arthritis. Design The effect of insulin on matrix synthesis,…”
    Get full text
    Journal Article
  12. 12

    Stability of protein formulations : investigation of surfactant effects by a novel EPR spectroscopic technique by BAM, N. B, RANDOLPH, T. W, CLELAND, J. L

    Published in Pharmaceutical research (1995)
    “…Surfactants are known to stabilize proteins and are often employed as additives in protein formulations. We have developed a method to study the interaction of…”
    Get full text
    Journal Article
  13. 13

    Comparison between light induced and chemically induced oxidation of rhVEGF by DUENAS, Eileen T, KECK, Rodney, DEVOS, Abraham, JONES, Andrew J. S, CLELAND, Jeffrey L

    Published in Pharmaceutical research (01-10-2001)
    “…The primary objective of this study was to compare the effects of light-and chemical-induced oxidation of recombinant human vascular endothelial growth factor…”
    Get full text
    Journal Article
  14. 14

    The stability of recombinant human growth hormone in poly(lactic-co-glycolic acid) (PLGA) microspheres by CLELAND, J. L, MAC, A, JONES, A. J. S, BOYD, B, YANG, J, DUENAS, E. T, YEUNG, D, BROOKS, D, HSU, C, CHU, H, MUKKU, V

    Published in Pharmaceutical research (01-04-1997)
    “…The development of a sustained release formulation for recombinant human growth hormone (rhGH) as well as other proteins requires that the protein be stable at…”
    Get full text
    Journal Article
  15. 15

    Solvent Evaporation Processes for the Production of Controlled Release Biodegradable Microsphere Formulations for Therapeutics and Vaccines by Cleland, Jeffrey L.

    Published in Biotechnology progress (1998)
    “…Novel drug delivery technologies have now evolved to allow the clinical production of new dosage forms. One new form, biodegradable microspheres, may have…”
    Get full text
    Journal Article
  16. 16
  17. 17

    Molten Globule Intermediate of Recombinant Human Growth Hormone: Stabilization with Surfactants by Bam, Narendra B., Cleland, Jeffrey L., Randolph, Theodore W.

    Published in Biotechnology progress (1996)
    “…We demonstrate that a surfactant‐stabilized molten globule intermediate exists for recombinant human growth hormone (rhGH), is very hydrophobic, and tends to…”
    Get full text
    Journal Article
  18. 18

    Use of infrared spectroscopy to assess secondary structure of human growth hormone within biodegradable microspheres by Yang, T H, Dong, A, Meyer, J, Johnson, O L, Cleland, J L, Carpenter, J F

    Published in Journal of pharmaceutical sciences (01-02-1999)
    “…The purpose of this study was to test the utility of infrared (IR) spectroscopy to determine protein secondary structure in biodegradable microspheres…”
    Get more information
    Journal Article
  19. 19

    Polyethylene Glycol Enhanced Protein Refolding by Cleland, Jeffrey L, Builder, Stuart E, Swartz, James R, Winkler, Marjorie, Chang, Judy Y, Wang, Daniel I. C

    Published in Bio/technology (New York, N.Y. 1983) (01-09-1992)
    “…Previous studies on the refolding of recombinant bovine carbonic anhydrase B (CAB) indicated that polyethylene glycol (PEG) significantly enhanced the recovery…”
    Get full text
    Journal Article
  20. 20